July 26, 2017 10:12 AM ET


Company Overview of Galderma S.A.

Company Overview

Galderma S.A. researches, develops, manufactures, and supplies dermatological products, and aesthetic and corrective medical solutions. It focuses on developing products for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis (fungal nail infections), pigmentary disorders, and skin cancer, as well as medical aesthetic and corrective solutions for skin senescence. The company also provides products for skin structure, dry skin, atopic dermatitis, scalp psoriasis, rosacea, seborrheic dermatitis, and other conditions. It sells products through a network of distributors and representatives worldwide. The company was founded in 1981 and is headquartered in Lausanne, Sw...

Avenue Gratta-Paille 2

World Trade Center

Lausanne,  1018


Founded in 1981


41 21 642 78 00


41 21 642 78 01

Key Executives for Galderma S.A.

Director of Finance, Director of Global Operations and Director of Corporate Services
Senior Director of Organizational Health
Corporate Development Director
Age: 55
General Manager of Spain and Portugal Operations
Age: 57
General Manager of Germany Operations
Compensation as of Fiscal Year 2017.

Galderma S.A. Key Developments

Galderma Presents at Russian Pharmaceutical Forum, May-16-2017

Galderma Presents at Russian Pharmaceutical Forum, May-16-2017 . Venue: Corinthia Saint-Petersburg Hotel, 57 Nevskij Prospect, St. Petersburg 191025, Russia.

Bioventus Announces New Agreement with Galderma

Bioventus announced it has a new agreement with Galderma for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. Financial terms of the transaction were not disclosed. Bioventus plans to file a premarket approval application with the FDA in early 2017 to bring DUROLANEto the US market in the near future. It owns the international rights to the productand has commercialized it outside of the United States for nearly 15 years. Bioventus currently markets and sells it in more than 25 countries including Canada, Mexico, Australia and much of Europe. Galderma manufactures DUROLANE and other HA products. The addition of DUROLANE tothe US portfolio for Bioventus will complement its newly launched three-injection HA GELSYN-3 and its popular five-injection HA SUPARTZ FX, giving the company an unmatched offering of options for patients, physicians and payers.

Galderma Receives Positive Opinion Through European Decentralised Procedure for Approval of EPIDUO® 0.3% / 2.5% gel (Adapalene / Benzoyl Peroxide) for Acne Patients

Galderma announced that it has received a Positive Opinion from 16 concerned European regulatory agencies for the market approval of EPIDUO 0.3% /2.5% gel (adapalene/benzoyl peroxide), for the cutaneous treatment of acne vulgaris, when comedones, numerous papules and pustules are present. With a once-daily application of EPIDUO 0.3% /2.5% gel in the evening to the entire affected areas of the face and the trunk, early signs of clinical improvement usually appear after 1 to 4 weeks of treatment. Galderma expects EPIDUO 0.3% /2.5% gel to be available in pharmacies in Europe as of 2017. EPIDUO 0.3% /2.5% gel contains a fixed-dose combination of Adapalene (3 mg/g) and Benzoyl Peroxide (BPO, 25 mg/g) as EPIDUO 0.1% /2.5% gel, but with a higher concentration of Adapalene, which provided increased clinical benefit in the subjects with numerous papulopustules treated with EPIDUO 0.3% /2.5% gel compared with the lower strength.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Galderma S.A., please visit www.galderma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.